138 related articles for article (PubMed ID: 9404486)
1. Juvenile chronic myelomonocytic leukemias: molecular and novel therapeutic basis.
Chomienne C; Cambier N; Baruchel A
Pathol Biol (Paris); 1997 Sep; 45(7):600-4. PubMed ID: 9404486
[TBL] [Abstract][Full Text] [Related]
2. Allogeneic transplantation: a therapeutic option for myelofibrosis, chronic myelomonocytic leukemia and Philadelphia-negative/BCR-ABL-negative chronic myelogenous leukemia.
Mittal P; Saliba RM; Giralt SA; Shahjahan M; Cohen AI; Karandish S; Onida F; Beran M; Champlin RE; de Lima M
Bone Marrow Transplant; 2004 May; 33(10):1005-9. PubMed ID: 15048141
[TBL] [Abstract][Full Text] [Related]
3. Management of the chronic leukemias: special considerations in the elderly patient. Part III rarer chronic myeloid leukemias.
Spiers AS
Hematology; 2002 Feb; 7(1):1-8. PubMed ID: 12171771
[TBL] [Abstract][Full Text] [Related]
4. p53 Protein expression in chronic myelomonocytic leukemia-1 correlates with progression to leukemia and a poor prognosis.
Hattori N; Fukuchi K; Nakamaki T; Homma M; Ariizumi H; Nakashima H; Maeda T; Saito B; Yamochi-Onizuka T; Yanagisawa K; Matsuda I; Ota H; Tomoyasu S
Acta Haematol; 2011; 125(4):242-6. PubMed ID: 21335959
[No Abstract] [Full Text] [Related]
5. Myelodysplastic and myeloproliferative disorders in children.
Hasle H
Curr Opin Pediatr; 2007 Feb; 19(1):1-8. PubMed ID: 17224655
[TBL] [Abstract][Full Text] [Related]
6. Reduced expression of H19 in bone marrow cells from chronic myeloproliferative disorders.
Bock O; Schlué J; Kreipe H
Leukemia; 2003 Apr; 17(4):815-6. PubMed ID: 12682647
[No Abstract] [Full Text] [Related]
7. Rational approaches to the design of therapeutics targeting molecular markers: the case of chronic myelogenous leukemia.
Saglio G; Morotti A; Mattioli G; Messa E; Giugliano E; Volpe G; Rege-Cambrin G; Cilloni D
Ann N Y Acad Sci; 2004 Dec; 1028():423-31. PubMed ID: 15650267
[TBL] [Abstract][Full Text] [Related]
8. Recent advances in diagnosis, molecular pathology and therapy of chronic myelomonocytic leukaemia.
Bacher U; Haferlach T; Schnittger S; Kreipe H; Kröger N
Br J Haematol; 2011 Apr; 153(2):149-67. PubMed ID: 21401573
[TBL] [Abstract][Full Text] [Related]
9. Chronic myelomonocytic leukemia monocytes uniformly display a population of monocytes with CD11c underexpression.
Sojitra P; Gandhi P; Fitting P; Kini AR; Alkan S; Velankar MM; Venkataraman G
Am J Clin Pathol; 2013 Nov; 140(5):686-92. PubMed ID: 24124148
[TBL] [Abstract][Full Text] [Related]
10. [Chronic myelomonocytic leukemia in adults].
Baudard M; Delmer A; Zittoun R
Pathol Biol (Paris); 1997 Sep; 45(7):605-11. PubMed ID: 9404487
[TBL] [Abstract][Full Text] [Related]
11. Juvenile myelomonocytic leukemia.
Emanuel PD
Curr Hematol Rep; 2004 May; 3(3):203-9. PubMed ID: 15087069
[TBL] [Abstract][Full Text] [Related]
12. High-throughput mutational screen of the tyrosine kinome in chronic myelomonocytic leukemia.
Tyner JW; Loriaux MM; Erickson H; Eide CA; Deininger J; MacPartlin M; Willis SG; Lange T; Druker BJ; Kovacsovics T; Maziarz R; Gattermann N; Deininger MW
Leukemia; 2009 Feb; 23(2):406-9. PubMed ID: 18615102
[No Abstract] [Full Text] [Related]
13. Juvenile myelomonocytic leukemia in a child with Crohn disease.
Oliver JW; Farnsworth B; Tonk VS
Cancer Genet Cytogenet; 2006 May; 167(1):70-3. PubMed ID: 16682290
[TBL] [Abstract][Full Text] [Related]
14. [Detection of BCR-ABL gene sequences using RT-PCR in patients with leukemia in the IX region. Chile].
Artigas CG; Melo A; Roa JC; Páez E; Vittini C; Arriagada M; González L; Pflaumer E; Roa I
Rev Med Chil; 2002 Jun; 130(6):623-30. PubMed ID: 12194684
[TBL] [Abstract][Full Text] [Related]
15. Molecular responses in patients with chronic myelogenous leukemia in chronic phase treated with imatinib mesylate.
Cortes J; Talpaz M; O'Brien S; Jones D; Luthra R; Shan J; Giles F; Faderl S; Verstovsek S; Garcia-Manero G; Rios MB; Kantarjian H
Clin Cancer Res; 2005 May; 11(9):3425-32. PubMed ID: 15867244
[TBL] [Abstract][Full Text] [Related]
16. Current status of vaccination therapy for leukemias.
Reichardt VL; Brossart P
Curr Hematol Rep; 2005 Jan; 4(1):73-6. PubMed ID: 15610663
[TBL] [Abstract][Full Text] [Related]
17. Chronic myelomonocytic leukemia: myeloproliferative variant.
Onida F; Beran M
Curr Hematol Rep; 2004 May; 3(3):218-26. PubMed ID: 15087071
[TBL] [Abstract][Full Text] [Related]
18. [Double t (3; 21) in acute myelomonocytic leukemia transformed from chronic myelomonocytic leukemia].
Arai Y; Handa T; Nakamura F; Takahashi W; Maki K; Mitani K
Rinsho Ketsueki; 2002 Sep; 43(9):865-7. PubMed ID: 12412294
[TBL] [Abstract][Full Text] [Related]
19. Apoptosis-based dual molecular targeting by INNO-406, a second-generation Bcr-Abl inhibitor, and ABT-737, an inhibitor of antiapoptotic Bcl-2 proteins, against Bcr-Abl-positive leukemia.
Kuroda J; Kimura S; Strasser A; Andreeff M; O'Reilly LA; Ashihara E; Kamitsuji Y; Yokota A; Kawata E; Takeuchi M; Tanaka R; Tabe Y; Taniwaki M; Maekawa T
Cell Death Differ; 2007 Sep; 14(9):1667-77. PubMed ID: 17510658
[TBL] [Abstract][Full Text] [Related]
20. Clinical, morphological, cytogenetic and molecular aspects of a series of Ph-negative chronic myeloid leukemias.
Aurich J; Duchayne E; Huguet-Rigal F; Bauduer F; Navarro M; Perel Y; Pris J; Caballin MR; Dastugue N
Hematol Cell Ther; 1998 Aug; 40(4):149-58. PubMed ID: 9766919
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
